Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma
(HCC). The mechanism underlying this effect is not completely understood. In this work we …

Aim: Forkhead box M1 (FoxM1) is a transcription factor that plays important roles in the
pathogenesis and progression of human cancers, including hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …

Background Sorafenib is recognized as a standard treatment for advanced hepatocellular
carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the …

The multikinase-inhibition action of sorafenib provides strong rationales for its combination
use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined …

Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

Background/Aim: Sorafenib is the medical reference for treatment of hepatocellular
carcinoma (HCC). Multiple forms of cytotoxicity are induced by sorafenib in HCC cells in vitro …

Aim This study aimed to compare the effects of the molecular targeted drugs, sorafenib and
lenvatinib, on the survival, invasion, and angiogenesis of hepatocellular carcinoma cells …

Sorafenib is a targeted drug for hepatocellular carcinoma (HCC), however, its efficacy is
limited. Nuclear factor erythroid 2‑related factor 2 (Nrf2) contributes to sorafenib resistance …

Both sorafenib and mammalian target of rapamycin inhibitor (mTORi) have antitumor effects.
This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients …